Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M

IRONWOOD PHARMACEUTICALS INC

2022-Q1 EPS reported $0.21 revenue$97,529,000

LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.
Total revenue $98M; GAAP net income $39M ($0.21 diluted EPS).
Adjusted EBITDA $58M, up from $46M; cash and equivalents $593M.
Full-year 2022 financial guidance reaffirmed; LINZESS exceeded $1B in 2021.
CEO cites progress in clinical trials and plans to in-license or acquire GI assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.